Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Selinexor in Combination with Standard or Reduced-Dose Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Multiple Myeloma

Su Shuai, Bin Xu, Chunrui Li, Di Wang, Xiwen Tong, Yi Zhu, Xia Mao, Min Xiao, Donghua Zhang

Blood (2024) 144 (Supplement 1): 7062.

https://doi.org/10.1182/blood-2024-204278

Published: 2024

Journal Articles

Imbalanced Expression of TACI Isoforms Regulated By TNFRSF13B Variants Promotes the Progression of Epstein-Barr Virus-Associated Lymphoproliferative Diseases

Xinyue Deng, Qiang Gao, Kefeng Shen, Wei Mu, Tong Ge, Jiachen Wang, Jianfeng Zhou, Yicheng Zhang, Dengju Li, Min Xiao

Blood (2024) 144 (Supplement 1): 125.

https://doi.org/10.1182/blood-2024-193440

Published: 2024

Journal Articles

Prognostic and Therapeutic Implications of Early Assessment in AML and MDS Patients Treated with Selinexor-Containing Chemotherapy-Free Regimen

Su Shuai, Bin Xu, Xiwen Tong, Yi Zhu, Shiyuan Zhang, Xia Mao, Zhiqiong Wang, Min Xiao, Donghua Zhang, Jia Wei

Blood (2024) 144 (Supplement 1): 6004.

https://doi.org/10.1182/blood-2024-205664

Published: 2024

Journal Articles

Development and Validation of Deep Learning Model for Diagnosis and Subtypes Differentiation of Myeloproliferative Neoplasms Using Clinical Data and Digital Pathology

Rong Wang, Zhongxun Shi, Yuan Zhang, Minghui Duan, Min Xiao, Suning Chen, Jianyao Huang, Xiaomei Hu, Jinhong Mei, Wenyi Shen, Yongyue Wei, Jianyong Li

Blood (2023) 142 (Supplement 1): 123.

https://doi.org/10.1182/blood-2023-184459

Published: 2023

Journal Articles

Real-World Experience with Selinexor -Containing Regimens in Post-Transplant AML/MDS Patients Who MRD Still Positive after First-Line Preemptive Treatment

Xiwen Tong, Shuai Su, Bin Xu, Xiaojian Zhu, Yizhou Peng, Jin Jie, Xia Mao, Min Xiao, Jay Mei, Donghua Zhang

Blood (2023) 142 (Supplement 1): 5837.

https://doi.org/10.1182/blood-2023-186006

Published: 2023

Journal Articles

TREM2 acts as a receptor for IL-34 to suppress acute myeloid leukemia in mice

Blood (2023) 141 (26): 3184–3198.

https://doi.org/10.1182/blood.2022018619

Published: 2023

Includes: Supplemental data

Journal Articles

The Safety and Efficacy of p CAR-19B, a Scfv Humanlized CD19-Directed CAR-T for Patients with Relapsed/Refactory (R/R) CD19+ B-ALL

Blood (2022) 140 (Supplement 1): 4625–4626.

https://doi.org/10.1182/blood-2022-162134

Published: 2022

Journal Articles

Outcomes of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) Patients with TP53 Gene Disruption Treated with CD19/22 Cocktail CAR T-Cell Therapy Alone or Incorporated with Autologous Stem Cell Transplantation (ASCT)

JIA Wei, Min Xiao, Zekai Mao, Yang Cao, Yi Xiao, Fankai Meng, Yicheng Zhang, Jianfeng Zhou, Liang Huang

Blood (2021) 138 (Supplement 1): 94.

https://doi.org/10.1182/blood-2021-147278

Published: 2021

Journal Articles

Osteocytes regulate neutrophil development through IL-19: a potent cytokine for neutropenia treatment

Min Xiao, Wuju Zhang, Wen Liu, Linlin Mao, Jincheng Yang, Le Hu, Sheng Zhang, Yaling Zheng, Anling Liu, Qiancheng Song, Yuhua Li, Guozhi Xiao, Zhipeng Zou, Xiaochun Bai

Blood (2021) 137 (25): 3533–3547.

https://doi.org/10.1182/blood.2020007731

Published: 2021

Includes: Supplemental data

Journal Articles

A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma

Blood (2021) 137 (21): 2890–2901.

https://doi.org/10.1182/blood.2020008936

Published: 2021

Includes: Supplemental data

Journal Articles

Anti CD19/22 Cocktail CAR T-Cell Therapy Can Improve the Outcomes of Patients with TP53-Mutated Relapsed/Refractory B-Cell Lymphoma

JIA Wei, MDPhD, Min Xiao, Zekai Mao, Na Wang, MD PhD, Chunrui Li, MDPhD, Yang Cao, Weimin Sun, Yi Xiao, Chaojiang Gu, Shangkun Zhang, PhD, Yicheng Zhang, Tongcun Zhang, PhD, Jianfeng Zhou, MD PhD, Liang Huang, MD

Blood (2020) 136 (Supplement 1): 43.

https://doi.org/10.1182/blood-2020-138947

Published: 2020

Journal Articles

CD19/CD22 CAR-T Cell Cocktail Therapy Following Autologous Transplantation in Patients with Relapsed/Refractory B-Cell Lymphomas

Yang Cao, Yi Xiao, Na Wang, MD PhD, Gaoxiang Wang, MDPhD, Xiaoxi Zhou, MDPhD, Liang Huang, MD, Liting Chen, PhD, Min Xiao, MD PhD, Tongcun Zhang, PhD, Yicheng Zhang, Jianfeng Zhou, MD PhD

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-140308

Published: 2020

Journal Articles

Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy

Wenyue Cao, Jia Wei, Na Wang, Hao Xu, Min Xiao, Lifang Huang, Yang Cao, Chunrui Li, Yi Xiao, Chaojiang Gu, Shangkun Zhang, Dengju Li, Yichen Zhang, Tongcun Zhang, Jianfeng Zhou, Liang Huang

Blood (2020) 136 (4): 516–519.

https://doi.org/10.1182/blood.2020004907

Published: 2020

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Fully Human Bcma Targeting CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma

Chunrui Li, MD PhD, Jue Wang, MD PhD, Di Wang, MD PhD, Guang Hu, Yongkun Yang, Xiaoxi Zhou, MD PhD, Li Meng, MD PhD, Zhenya Hong, MD PhD, Liting Chen, PhD, Xia Mao, MD PhD, Min Xiao, MD PhD, Jianfeng Zhou, MD PhD

Blood (2019) 134 (Supplement_1): 929.

https://doi.org/10.1182/blood-2019-128468

Published: 2019

Journal Articles

Molecular Classification of Small B-Cell Lymphomas Using Digital Multiplexed Gene Expression Applicable to Formalin-Fixed Paraffin-Embedded Tissues

Min Xiao, MD PhD, Jianfeng Zhou, MD PhD, Wei Zhang, MD

Blood (2019) 134 (Supplement_1): 5770.

https://doi.org/10.1182/blood-2019-130446

Published: 2019

Journal Articles

Co-Transplantation of Mesenchymal Stem Cells Further Improves the Prognosis of Allo-HSCT in the Treatment of High Risk and Refractory/Relapse Hematologic Malignancies: A Single-Center Retrospective Study of 175 Patients

Jinhua Ren, Xiaofeng Luo, Minmin Chen, Min Xiao, Qian Li, Kangni Lin, Zhihong Zheng, Zhizhe Chen, Jianda Hu, PhD, Ting Yang

Blood (2019) 134 (Supplement_1): 5721.

https://doi.org/10.1182/blood-2019-127595

Published: 2019

Journal Articles

Droplet Digital PCR Monitoring of TP53 Mutated Circulating Tumor DNA Levels in Lymphoma Patients

Xiaolu Long, Jia Gu, Yaoyao Lou, Qian Xu, Haodong Cai, MD, Wei Zhang, MD, Kefeng Shen, Min Xiao, MD PhD, Yicheng Zhang, MD PhD, Liting Chen, PhD, Jianfeng Zhou, PhD

Blood (2018) 132 (Supplement 1): 4106.

https://doi.org/10.1182/blood-2018-99-113825

Published: 2018

Journal Articles

Clinical and Genetic Features of Epstein-Barr Virus-Triggered Late-Onset Primary Hemophagocytic Lymphohistiocytosis: 10 Pedigrees Study

Chunrui Li, MD PhD, Lili Gao, Li Yang, Min Xiao, MD PhD, Jianfeng Zhou, MD PhD, Yicheng Zhang, MD PhD

Blood (2018) 132 (Supplement 1): 3903.

https://doi.org/10.1182/blood-2018-99-114009

Published: 2018

Journal Articles

Targeted Next-Generation Sequencing of Cell-Free DNA in Diffuse Large B-Cell Lymphoma

Wei Zhang, MD, Min Xiao, MD PhD, Jianfeng Zhou, PhD, Ken H. Young, MD PhD

Blood (2018) 132 (Supplement 1): 4212.

https://doi.org/10.1182/blood-2018-99-116847

Published: 2018

Journal Articles

CAR22/19 Cocktail Therapy for Patients with Refractory/Relapsed B-Cell Malignancies

Liang Huang, MDPhD, Na Wang, MD PhD, Yang Cao, Chunrui Li, MDPhD, Yi Xiao, MD PhD, Min Xiao, MD PhD, Xiaoxi Zhou, MD, PhD, Gaoxiang Wang, MDPhD, Zhenya Hong, MD, PhD, Miao Zhen, MD, PhD, Weixu Meng, MD PhD, Bin Zhang, PhD, Yicheng Zhang, MDPhD, Guido Marcucci, Tongcun Zhang, PhD, Jianfeng Zhou, PhD

Blood (2018) 132 (Supplement 1): 1408.

https://doi.org/10.1182/blood-2018-99-113714

Published: 2018

NARROW

Selinexor in Combination with Standard or Reduced-Dose Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Multiple Myeloma

Imbalanced Expression of TACI Isoforms Regulated By TNFRSF13B Variants Promotes the Progression of Epstein-Barr Virus-Associated Lymphoproliferative Diseases

Prognostic and Therapeutic Implications of Early Assessment in AML and MDS Patients Treated with Selinexor-Containing Chemotherapy-Free Regimen

Development and Validation of Deep Learning Model for Diagnosis and Subtypes Differentiation of Myeloproliferative Neoplasms Using Clinical Data and Digital Pathology

Real-World Experience with Selinexor -Containing Regimens in Post-Transplant AML/MDS Patients Who MRD Still Positive after First-Line Preemptive Treatment

TREM2 acts as a receptor for IL-34 to suppress acute myeloid leukemia in mice

The Safety and Efficacy of p CAR-19B, a Scfv Humanlized CD19-Directed CAR-T for Patients with Relapsed/Refactory (R/R) CD19+ B-ALL

Outcomes of Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) Patients with TP53 Gene Disruption Treated with CD19/22 Cocktail CAR T-Cell Therapy Alone or Incorporated with Autologous Stem Cell Transplantation (ASCT)

Osteocytes regulate neutrophil development through IL-19: a potent cytokine for neutropenia treatment

A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma

Anti CD19/22 Cocktail CAR T-Cell Therapy Can Improve the Outcomes of Patients with TP53-Mutated Relapsed/Refractory B-Cell Lymphoma

CD19/CD22 CAR-T Cell Cocktail Therapy Following Autologous Transplantation in Patients with Relapsed/Refractory B-Cell Lymphomas

Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy

Efficacy and Safety of Fully Human Bcma Targeting CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma

Molecular Classification of Small B-Cell Lymphomas Using Digital Multiplexed Gene Expression Applicable to Formalin-Fixed Paraffin-Embedded Tissues

Co-Transplantation of Mesenchymal Stem Cells Further Improves the Prognosis of Allo-HSCT in the Treatment of High Risk and Refractory/Relapse Hematologic Malignancies: A Single-Center Retrospective Study of 175 Patients

Droplet Digital PCR Monitoring of TP53 Mutated Circulating Tumor DNA Levels in Lymphoma Patients

Clinical and Genetic Features of Epstein-Barr Virus-Triggered Late-Onset Primary Hemophagocytic Lymphohistiocytosis: 10 Pedigrees Study

Targeted Next-Generation Sequencing of Cell-Free DNA in Diffuse Large B-Cell Lymphoma

CAR22/19 Cocktail Therapy for Patients with Refractory/Relapsed B-Cell Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only